Litigation Details for Snipe v. Gilead Sciences, Inc. (N.D. Cal. 2019)
✉ Email this page to a colleague
Snipe v. Gilead Sciences, Inc. (N.D. Cal. 2019)
Docket | ⤷ Sign Up | Date Filed | 2019-05-20 |
Court | District Court, N.D. California | Date Terminated | |
Cause | 15:1 Antitrust Litigation | Assigned To | Edward Milton Chen |
Jury Demand | Plaintiff | Referred To | |
Patents | 6,043,230; 6,642,245; 6,703,396; 7,390,791; 7,803,788; 8,754,065; 9,296,769 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Snipe v. Gilead Sciences, Inc.
Biologic Drugs cited in Snipe v. Gilead Sciences, Inc.
Details for Snipe v. Gilead Sciences, Inc. (N.D. Cal. 2019)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2019-05-20 | 1 | Complaint | 5,935,946; 5,977,089; and 6,043,230 (the “TDF Patents”). Teva asserted that the TDF patents 23 were invalid…listed patent(s) and/or the patent is invalid and 18 unenforceable. Simply by listing the patents in the…ANDA applicant for patent 23 infringement. If the brand manufacturer brings a patent infringement action…legitimate patent protection or ferret out invalid, unenforceable, or 24 narrow drug patents. 25 …even after the 21 patents on them expired. 22 86. Gilead’s patents on TDF, FTC, and TDF | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |